Citicoline vs Alpha-GPC: Which Should You Take?

Citicoline and alpha-GPC are the two choline compounds people actually compare when they build a focus stack, and the honest answer to "which is better" depends on what you want the choline for. One point of disclosure before we start: Vyvamind contains citicoline, so we have a position. What we can do is show you the trials behind both compounds, state their limits plainly, and let you check every claim against the original papers linked throughout.

What is the difference between citicoline and alpha-GPC?

Both molecules deliver choline to the brain; the real difference is the other half of each molecule. Citicoline, also called CDP-choline, is choline bound to cytidine. Alpha-GPC (choline alphoscerate) is choline bound to a glycerophosphate backbone left over when phosphatidylcholine is stripped of its fatty acids.

That structural difference decides what arrives in your bloodstream. Research in humans shows that an oral dose of citicoline is split during absorption and raises plasma levels of two things: choline and uridine. Each travels to the brain separately, where the choline feeds acetylcholine and membrane synthesis while the uridine re-enters the same membrane-building pathway from the other side. Grieb's mechanistic review describes the net effect as "slowing down of phospholipid breakdown and acceleration of phospholipid resynthesis necessary for membrane repair".

Alpha-GPC takes a shorter road. A 2023 review of choline supplements notes that after oral administration it "can be readily metabolized to PC, the active form of choline that is able to increase the release of the neurotransmitter ACh". In plain terms, alpha-GPC is an efficient choline courier. Citicoline is a courier that carries a second package.

Which one delivers more choline?

Alpha-GPC wins on raw choline, and it is no contest. The same 2023 review puts its choline content at "41% of choline by weight", so a 300 mg capsule carries roughly 120 mg of choline. Citicoline's molecule is much heavier because of the cytidine it carries: choline makes up about a fifth of its weight, which follows from simple arithmetic on the two molecular weights (104 of 488 g/mol).

Whether that matters depends on what you think the missing weight is doing. If your only goal is dietary choline per milligram, alpha-GPC is the denser source. The case for citicoline is that the cytidine fraction is doing work of its own: it circulates as uridine and supplies the other precursor that membrane phospholipid synthesis needs. You are buying two inputs in one molecule rather than a concentrated dose of one.

What has citicoline shown in healthy adults?

Citicoline's distinguishing feature is that its key trials were run on healthy people at ordinary supplement doses. Three randomized, placebo-controlled studies matter most:

• Attention, women aged 40 to 60. In McGlade and colleagues' 2012 trial, 28 days of citicoline at 250 or 500 mg per day reduced errors on a sustained-attention task versus placebo. The authors concluded citicoline "was associated with improved attentional focus and inhibition" in healthy adults.
• Attention and motor speed, adolescent males. A second trial by the same group found improved attention (p = 0.02) and psychomotor speed (p = 0.03) after 28 days at the same doses.
• Memory, adults aged 50 to 85. Nakazaki and colleagues (2021) gave 500 mg daily for 12 weeks to 100 healthy older adults with the ordinary memory slippage of aging. Episodic memory improved versus placebo (p = 0.0025). The trial's primary outcome, a spatial working-memory test, did not reach significance, which weakens the result and deserves saying out loud.

There is also imaging evidence: a six-week spectroscopy study in 16 healthy adults found increased frontal-lobe phosphocreatine and ATP-related metabolites after daily citicoline, a shift in the brain's energy chemistry rather than any felt buzz.

Two weaknesses run through this literature. The samples were small, and the attention and memory trials had industry funding or industry-affiliated authors. Neither point invalidates a randomized design, but a careful reader should weigh both. The full evidence picture, including a European regulator's colder reading of it, is in our citicoline benefits guide.

What has alpha-GPC shown?

Alpha-GPC's strongest human evidence sits in clinical populations, at doses well above what supplements provide. The largest oral trial, published by De Jesus Moreno Moreno in 2003, gave 1,200 mg per day for 180 days to 261 older patients with mild to moderate Alzheimer's dementia and found cognitive scores improved while the placebo group declined. That is a genuine result in that population and at that dose. It tells you little about a healthy adult taking a 300 mg capsule, and no supplement is a treatment for dementia.

In healthy people the record is thin. The best available study, a 2021 trial in Nutrients, gave 39 healthy volunteers 400 mg per day for two weeks and reported higher self-rated motivation at night versus placebo. It was small and single-blind, and it measured mood ratings rather than cognitive performance. Nothing in the healthy-adult literature on alpha-GPC matches the placebo-controlled attention and memory testing that citicoline has been put through.

Is there a direct head-to-head study?

One exists, and it deserves careful reading. A 2025 systematic review and meta-analysis pooled the only three randomized trials that compared the compounds directly: 358 older patients with vascular or multi-infarct dementia, each compound given at 1,000 mg per day for 90 days by intramuscular injection. Alpha-GPC came out ahead on global clinical scores, and the authors concluded it "is more effective than citicoline in improving the clinical conditions of dementia patients". On the memory and word-fluency tests specifically, the two compounds did not differ.

Read the conditions back, though. The compounds were injected rather than swallowed, and the patients were elderly people with dementia receiving hospital doses. That evidence answers a clinical question. It does not tell you which capsule better supports focus in a healthy adult, because that comparison has never been run. Anyone quoting this meta-analysis as proof that one supplement "beats" the other is stretching it past what it measured.

How do the doses and safety records compare?

Citicoline's trial doses in healthy adults are the same doses supplements use, 250 to 500 mg per day, and its tolerability record is long and clean. Grieb's review calls it "non-toxic and very well tolerated", with side effects mostly limited to mild digestive upset.

Alpha-GPC's oral evidence used 400 mg per day in the healthy-volunteer study and 1,200 mg per day in the dementia trial, so the dose behind its strongest results is several times the typical supplement serving. It is generally well tolerated in trials. One safety signal does need reporting: a 2021 cohort study in JAMA Network Open followed over 12 million Koreans aged 50 and older for ten years and found alpha-GPC use "was associated with a higher 10-year incident stroke risk in a dose-response manner after adjusting for traditional cerebrovascular risk factors". The study has real limits. It was observational, so it can show an association but cannot prove causation. Its setting was also medical use of alpha-GPC within the Korean health system rather than supplement use, and no randomized trial has tested the finding. It is unresolved rather than damning. If you are over 50 or have cardiovascular risk factors, it is a fair thing to raise with your doctor before choosing alpha-GPC.

Citicoline vs alpha-GPC at a glance

Which should you take for focus?

If you are a healthy adult choosing a daily choline compound for focus, the trial map points to citicoline, because its evidence was generated in people like you at doses you can actually buy. That reasoning, and no secret about it, is why citicoline anchors the Vyvamind formula; the full logic is on our research and formulation page. Alpha-GPC remains a reasonable compound with real clinical results, and someone persuaded by choline density or the head-to-head dementia data could defend picking it. The evidence for that choice just was not collected in healthy people.

Either way, treat any choline compound as the slow layer of a stack. Neither gives you an acute lift; the trial effects took weeks of daily use to appear. The fast layer is a different pairing, covered in our L-theanine and caffeine guide. And if you would rather start from a finished formula than assemble the pieces yourself, our guide to the best nootropic supplement explains how we weigh choline sources alongside the rest of the evidence.